Critical role of type 1 plasminogen activator inhibitor (PAI-1) in early host defense against nontypeable Haemophilus influenzae (NTHi) infection

Biochemical and Biophysical Research Communications

Volumn 414, Issue 1, 2011, Pages 67-72

  Lim, Jae Hyang ^a,b   Woo, Chang Hoon ^c   Li, Jian Dong ^a,b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c Yeungnam University College of Medicine   (South Korea)

Author keywords

Inflammation; Innate immune response; Nontypeable Haemophilus influenzae; Pneumonia; Type 1 plasminogen activator inhibitor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MYELOID DIFFERENTIATION FACTOR 88; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TOLL LIKE RECEPTOR 2; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CLEARANCE; BLOOD CLOTTING; ENZYME ACTIVATION; EPITHELIUM CELL; FIBRINOLYSIS; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HELA CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; MAP KINASE KINASE 3; MICE; MICE, KNOCKOUT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PULMONARY ALVEOLI; TISSUE PLASMINOGEN ACTIVATOR; UP-REGULATION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

BACTERIA (MICROORGANISMS); HAEMOPHILUS INFLUENZAE; MUS; NEGIBACTERIA;

EID: 80054087827     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.09.023     Document Type: Article

References (30)

1. Hemila H., Louhiala P. Vitamin C for preventing and treating pneumonia. Cochrane Database of Systematic Reviews 2007, CD005532.
2. Janeway C.A., Medzhitov R. Innate immune recognition. Annual Review of Immunology 2002, 20:197-216.
3. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
4. Werling D., Jungi T.W. TOLL-like receptors linking innate and adaptive immune response. Veterinary Immunology and Immunopathology 2003, 91:1-12.
5. Brown J., Wang H., Hajishengallis G.N., Martin M. TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. Journal of Dental Research 2011, 90:417-427.
6. O'Neill L.A. Signal transduction pathways activated by the IL-1 receptor/toll-like receptor superfamily. Current Topics in Microbiology and Immunology 2002, 270:47-61.
7. Baumann H., Gauldie J. The acute phase response. Immunology Today 1994, 15:74-80.
8. Germolec D.R., Frawley R.P., Evans E. Markers of inflammation. Methods in Molecular Biology 2010, 598:53-73.
9. Hermans P.W., Hazelzet J.A. Plasminogen activator inhibitor type 1 gene polymorphism and sepsis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2005, 41(Suppl. 7):S453-S458.
10. Dellas C., Loskutoff D.J. Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thrombosis and Haemostasis 2005, 93:631-640.
11. Fay W.P. Plasminogen activator inhibitor 1, fibrin, and the vascular response to injury. Trends in Cardiovascular Medicine 2004, 14:196-202.
12. Kucharewicz I., Kowal K., Buczko W., Bodzenta-Lukaszyk A. The plasmin system in airway remodeling. Thrombosis Research 2003, 112:1-7.
13. Lijnen H.R. Pleiotropic functions of plasminogen activator inhibitor-1. Journal of Thrombosis and Haemostasis 2005, 3:35-45.
14. Shetty S., Padijnayayveetil J., Tucker T., Stankowska D., Idell S. The fibrinolytic system and the regulation of lung epithelial cell proteolysis, signaling, and cellular viability. American Journal of Physiology. Lung Cellular and Molecular Physiology 2008, 295:L967-L975.
15. Lim J.H., Stirling B., Derry J., Koga T., Jono H., Woo C.H., Xu H., Bourne P., Ha U.H., Ishinaga H., Andalibi A., Feng X.H., Zhu H., Huang Y., Zhang W., Weng X., Yan C., Yin Z., Briles D.E., Davis R.J., Flavell R.A., Li J.D. Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 2007, 27:349-360.
16. Wang B., Lim D.J., Han J., Kim Y.S., Basbaum C.B., Li J.D. Novel cytoplasmic proteins of nontypeable Haemophilus influenzae up-regulate human MUC5AC mucin transcription via a positive p38 mitogen-activated protein kinase pathway and a negative phosphoinositide 3-kinase-Akt pathway. The Journal of Biological Chemistry 2002, 277:949-957.
17. J.H. Lim, U. Ha, A. Sakai, C.H. Woo, S.M. Kweon, H. Xu, J.D. Li, Streptococcus pneumoniae synergizes with nontypeable Haemophilus influenzae to induce inflammation via upregulating TLR2, BMC Immunology 9 (2008) 40.
18. Jono H., Shuto T., Xu H., Kai H., Lim D.J., Gum J.R., Kim Y.S., Yamaoka S., Feng X.H., Li J.D. Transforming growth factor-beta -Smad signaling pathway cooperates with NF-kappa B to mediate nontypeable Haemophilus influenzae-induced MUC2 mucin transcription. The Journal of Biological Chemistry 2002, 277:45547-45557.
19. T. Shuto, A. Imasato, H. Jono, A. Sakai, H. Xu, T. Watanabe, D.D. Rixter, H. Kai, A. Andalibi, F. Linthicum, Y.L. Guan, J. Han, A.C. Cato, D.J. Lim, S. Akira, J.D. Li, Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase, The Journal of Biological Chemistry 277 (2002) 17263-17270.
20. Lim J.H., Ha U.H., Woo C.H., Xu H., Li J.D. CYLD is a crucial negative regulator of innate immune response in Escherichia coli pneumonia. Cellular Microbiology 2008, 10:2247-2256.
21. Lim J.H., Jono H., Koga T., Woo C.H., Ishinaga H., Bourne P., Xu H., Ha U.H., Li J.D. Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenza-induced inflammation in the middle ear and lung of mice. PLoS One 2007, 2:e1032.
22. Bergmann S., Hammerschmidt S. Fibrinolysis and host response in bacterial infections. Thrombosis and Haemostasis 2007, 98:512-520.
23. Janciauskiene S. Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles. Biochimica et Biophysica Acta 2001, 1535:221-235.
24. E. Abraham, M.R. Gyetko, K. Kuhn, J. Arcaroli, D. Strassheim, J.S. Park, S. Shetty, S. Idell, Urokinase-type plasminogen activator potentiates lipopolysaccharide-induced neutrophil activation, Journal of Immunology 170 (2003) 5644-5651.
25. Goolaerts A., Lafargue M., Song Y., Miyazawa B., Arjomandi M., Carles M., Roux J., Howard M., Parks D.A., Iles K.E., Pittet J.F. PAI-1 is an essential component of the pulmonary host response during Pseudomonas aeruginosa pneumonia in mice. Thorax 2011, 66:788-796.
26. R. Renckens, J.J. Roelofs, P.I. Bonta, S. Florquin, C.J. de Vries, M. Levi, P. Carmeliet, C. van't Veer, T. van der Poll, Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia, Blood 109 (2007) 1593-1601.
27. Shetty S., Bdeir K., Cines D.B., Idell S. Induction of plasminogen activator inhibitor-1 by urokinase in lung epithelial cells. The Journal of Biological Chemistry 2003, 278:18124-18131.
28. Jaulmes A., Sansilvestri-Morel P., Rolland-Valognes G., Bernhardt F., Gaertner R., Lockhart B.P., Cordi A., Wierzbicki M., Rupin A., Verbeuren T.J. Nox4 mediates the expression of plasminogen activator inhibitor-1 via p38 MAPK pathway in cultured human endothelial cells. Thrombosis Research 2009, 124:439-446.
29. Prabhakaran P., Ware L.B., White K.E., Cross M.T., Matthay M.A., Olman M.A. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. American Journal of Physiology. Lung Cellular and Molecular Physiology 2003, 285:L20-28.
30. Tsangaris I., Tsantes A., Bonovas S., Lignos M., Kopterides P., Gialeraki A., Rapti E., Orfanos S., Dimopoulou I., Travlou A., Armaganidis A. The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS. Thrombosis Research 2009, 123:832-836.